Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

Fig. 2

a Real time qPCR analysis of PD-L1 mRNA expression in H460 and H1299 cell lines not treated (ctr), treated with selumetinib (mek-i) or stimulated with PMA (PMA). Results were normalized to 18S mRNA and analyzed by ΔCt method. One way ANOVA test followed by Tukey’s test were used for statistical analysis. **p < 0.01; ***p < 0.001. b Western blot analysis of MEK, phospho-MEK, MAPK, phopsho-MAPK, MHC-I and PD-L1 on protein lysates from NSCLC cell lines H460 and H1299 treated with selumetinib at indicated dose. β-actin was included as a loading control. c Levels of PD-L1 were measured in total protein extracts of H1299 and H460 cells that were transfected with scrambled (Scr) small interfering RNAs (siRNAs), or transfected with STAT3 siRNAs. β-Actin protein was used as a loading control for western blot analysis. d ChIP Assay evaluating the binding of NF-κB (p65) to the PD-L1 promoter in H1299 cells untreated or treated with MEK-i or PMA

Back to article page